Years Ahead in HIV Prevention Research

Time to Market

Prevention Product	Q1 Q2 Q3 Q4 Q1	2023 2024 Q1 Q2 Q3 Q4 Q1	2025 202 Q2 Q3 Q4 Q1 Q2	26 2027 2028 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Vaginal Ring	Dapivirine monthly Multiple regulatory approvals WHO Guidelines	Multiple implementation science Selected Global Fund procureme		 Demonstrated modest efficacy Unclear demand and limited initial supply Initial price ~\$180/yr Oct 2023: A memorandum of understanding reached on a product license with Kiara 3-monthly ring currently in development and could be submitted to regulators in 2025 Opportunity to build market and platforms for vaginal rings
Long-Acting Injectables	Cabotegravir One intramuscular injection (3ml) every 2 months WHO Guidelines	Selected Global Fund and PEP		 Demonstrated high efficacy Unclear demand and limited initial supply Initial LMIC price ~\$240/yr; 2024: ~\$180/yr; 2025: ~\$160/yr Mar 2023: MPP & Viiv licensed to 3 generics with likely regulatory submission by 2027 4-monthly formulation currently in development, with regulatory submission expected early 2026 Opportunity to build market and platforms for injectables
	Lenacapavir Two subcutaneous injections (1.5 ml each) every 6 months Phase 3: PURPOSI	ion out out and a soluted additional transfer	by US FDA, Possible product intro	 Demonstrated very high efficacy Dec 2024: Global Fund & PEPFAR commit to reaching 2 million users in first 3 yrs Initial LMIC price unclear; 2027: generic price of ~\$55 for loading dose + injections and ~\$40 for ongoing use Oct 2024: Gilead licensed to 6 generics with likely
Oral PrEP	F/TAF daily Phase	e 3: part of PURPOSE 1	Possible regulatory approvals	 regulatory submission by 2027 Once-yearly formulation currently in development, with regulatory submission expected in 2027 Opportunity to understand if market can bear 2 injectables
	MK-8527 monthly	Phase 2a: MK-8527-07		VE-10 launched in Q3 2025, and pected to launch in Q4 of 2025



Dual Prevention Pill

Co-formulated
TDF/FTC and
ethinyl estradiol/
levonorgestrel
oral contraceptive
pill
daily

Pilot bioequivalence (BE) study



Possible regulatory approvals

Possible product introduction

Acceptability Study: HPTN 104